Molecular Basis of Cervical Neoplasia

The Cervix: Second Edition

Volumn , Issue , 2009, Pages 277-288

  Stubenrauch, Frank ^a   Iftner, Thomas ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Bovine papillomavirus (BPV); Cellular gene polymorphism; Cervical neoplasia molecular basis; HPV genome; Human leucocyte antigen haplotypes; Long control region (LCR); Viral DNA integration

Indexed keywords

EID: 70350492199     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444312744.ch19     Document Type: Chapter

References (111)

1. Abba MC, Mouron SA, Gomez MA et al. (2003). Association of human papillomavirus viral load with HPV16 and high-grade intraepithelial lesion. International Journal of Gynecological Cancer, 13: 154-158.
2. Barbosa MS, Vass WC, Lowy DR et al. (1991). In vitro biological activities of the E6 and E7 genes vary among human papillomaviruses of different oncogenic potential. Journal of Virology, 65: 292-298.
3. Beer-Romero P, Glass S, Rolfe M (1997). Antisense targeting of E6AP elevates p53 in HPV-infected cells but not in normal cells. Oncogene, 14: 595-602.
4. Berg JW, Lampe JG (1981). High-risk factors in gynaecologic cancer. Cancer, 48: 429-441.
5. Billich A (2003). HPV vaccine MedImmune/GlaxoSmithKline. Current Opinion in the Investigation of Drugs, 4: 210-213.
6. Blohme I, Brynger H (1985). Malignant disease in renal transplant patients. Transplantation, 39: 23-25.
7. Bontkes HJ, Walboomers JM, Meijer CJ et al. (1998). Specific HLA class I down-regulation is an early event in cervical dysplasia associated with clinical progression. Lancet, 351: 187-188.
8. Bosch XF, Manos MM, Muñoz N et al.(1995) Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. Journal of the National Cancer Institute 87: 796-802.
9. Bosch XF, Lorincz A, Muñoz N et al. (2002). The causal relation between human papillomavirus and cervical cancer. Journal of Clinical Pathology, 55: 244-265.
10. Boyer SN, Wazer DE, Band V (1996). E7 protein of human papilloma virus-16 induces degradation of retinoblastoma protein through the ubiquitin-proteasome pathway. Cancer Research, 56: 4620-4624.
11. Brady CS, Duggan-Keen MF, Davidson JA et al. (1999). Human papillomavirus type 16 E6 variants in cervical carcinoma: relationships to host genetic factors and clinical parameters. Journal of General Virology, 80: 3233-3240.
12. Chan PK, Lam CW, Cheung TH et al. (2002). Association of human papillomavirus type 58 variant with the risk of cervical cancer. Journal of the National Cancer Institute, 94: 1249-1253.
13. Chellappan S, Kraus VB, Kroger B et al. (1992). Adenovirus E1A, simians virus 40 tumor antigen, and human papillomavirus E7 protein share the capacity to disrupt the interaction between transcription factor E2F and the retinoblastoma gene product. Proceedings of the National Academy of Sciences of the USA, 89: 4549-4553.
14. Cheng S, Schmidt-Grimminger DC, Murant T et al. (1995). Differentiation-dependent up-regulation of the human papillomavirus E7 gene reactivates cellular DNA replication in suprabasal differentiated keratinocytes. Genes and Development, 9: 2335-2349.
15. Cogliano V, Baan R, Straif K et al. and the IARC Monograph Working Group (2005). Carcinogenicity of human papillomaviruses. Lancet Oncology, 6: 204.
16. Cullen AP, Reid R, Campion M et al. (1991). Analysis of the physical state of different human papillomavirus DNAs in intraepithelial and invasive cervical neoplasm. Journal of Virology, 65: 606-612.
17. Davies R, Hicks R, Crook T et al. (1993). Human papillomavirus type 16 E7 associates with a histone H1 kinase and with p107 through sequences necessary for transformation. Journal of Virology, 67: 2521-2528.
18. de Villiers EM, Lavergne D, McLaren K et al.(1997) Prevailing papillomavirus types in non-melanoma carcinomas of the skin in renal allograft recipients. International Journal of Cancer 73: 356-361.
19. de Villiers EM, Fauquet C, Broker TR et al. (2004). Classification of papillomaviruses. Virology, 324: 17-27.
20. Dong SM, Kim HS, Rha SH et al. (2001). Promoter hypermethylation of multiple genes in carcinoma of the uterine cervix. Clinics in Cancer Research, 7: 1982-1986.
21. Duggan-Keen MF, Keating PJ, Stevens FR et al. (1996). Immunogenetic factors in HPV-associated cervical cancer: influence on disease progression. European Journal of Immunogenetics, 23: 275-284.
22. Dyson N, Howley PM, Münger K et al. (1989). The human papilloma virus-16 E7 oncoprotein is able to bind to the retinoblastoma gene product. Science, 243: 934-937.
23. Dyson N, Guida P, Munger K et al. (1992). Homologous sequences in adenovirus EIA and human papillomavirus E7 proteins mediate interaction with the same set of cellular proteins. Journal of Virology, 66: 6893-6902.
24. Elbel M, Carl S, Spaderna S et al. (1997). A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation of their transforming potential. Virology, 239: 132-149.
25. Ellis JR, Keating PJ, Baird J et al.(1995) The association of an HPV16 oncogene variant with HLA-B7 has implications for vaccine design in cervical cancer. Nature Medicine 1:464-470.
26. Ferenczy A, Mitao M, Nagai N et al. (1985). Latent papillomavirus and recurring genital warts. New England Journal of Medicine, 313: 784-788.
27. Fraser IH (2004). Prevention of cervical cancer through papillomavirus vaccination. Nature Immunology, 4: 46-54.
28. Fuchs PG. Girardi F, Pfister H (1989) Human papillomavirus 16 DNA in cervical cancers and in lymph nodes of cervical cancer patients:a diagnostic marker for early metastases? International Journal of Cancer 43: 41-44.
29. Funk JO, Waga S, Harry JB et al. (1997). Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. Genes and Development, 11: 2090-2100.
30. Gage JR, Meyers C, Wettstein FO (1990). The E7 proteins of the nononcogenic human papillomavirus type 6b (HPV-6b) and of the oncogenic HPV-16 differ in retinoblastoma protein binding and other properties. Journal of Virology, 64: 723-730.
31. Giannoudis A, Graham DA, Southern SA et al. (1999). p53 codon 72 ARG/PRO polymorphism is not related to HPV type or lesion grade in low- and high-grade squamous intraepithelial lesions and invasive squamous carcinoma of the cervix. International Journal of Cancer, 83: 66-69.
32. Goodman MT, McDuffie K, Hernandez B et al.(2001) Association of methylenetetrahydrofolate reductase polymorphism C677T and dietary folate with the risk of cervical dysplasia. Cancer Epidemiology Biomarkers and Prevention 10: 1275-1280.
33. Halbert CL, Demers GW, Galloway DA (1991). The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. Journal of Virology, 65: 473-478.
34. Halbert CL, Demers GW, Galloway DA (1992). The E6 and E7 genes of human papillomavirus type 6 have weak immortalising activity in human epithelial cells. Journal of Virology, 66: 2125-2134.
35. Harima Y, Sawada S, Nagata K et al. (2001). Polymorphism of the WAF1 gene is related to susceptibility to cervical cancer in Japanese women. International Journal of Molecular Medicine, 7: 261-264.
36. Harper DM, Franco EL, Wheeler CM et al. (2004). Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection of human papillomavirus type 16 and 18 in young women; a randomised controlled trial. Lancet, 364: 1757-1765.
37. Hayes VM, Hofstra RAM, Buys CH et al. (1998). Homozygous arginine-72 in wild type p53 and risk of cervical cancer. Lancet, 351: 1756.
38. Hecht JL, Kadish AS, Jiang G et al. (1995). Generic characterization of the human papillomavirus (HPV) 18 E2 gene in clinical specimens suggests the presence of a subtype with decreased oncogenic potential. International Journal of Cancer, 60: 369-376.
39. Helland A, Olsen AO, Gjoen K et al. (1998). An increased risk of cervical intra-epithelial neoplasia grade II-III among human papillomavirus positive patients with the HLA-DQA1*0102-DQB1*0602 haplotype:a population-based case-control study of Norwegian women. International Journal of Cancer, 76: 19-24.
40. Hildesheim A, Wang SS (2002). Host and viral genetics and risk of cervical cancer: a review. Virus Research, 89: 229-240.
41. Hildesheim A, Schiffman M, Brinton LA et al. (1998). p53 polymorphism and risk of cervical cancer. Nature, 396: 531-532.
42. Huibregtse JM, Scheffner M, Howley PM (1991). A cellular protein mediates association of p53 with the E6 oncoprotein of human papillomavirus types 16 or 18. EMBO Journal, 10: 4129-4135.
43. IARC World Health Organization (2005) IARC Handbooks of Cancer Prevention, Vol. 10: Cervical Cancer Screening. Lyon: IARC Press.
44. Iftner T, Elbel M, Schopp B et al. (2002). Interference of papillomavirus E6 protein with single-strand break repair by interaction with XRCC1. EMBO Journal, 21 (17): 4741-4748.
45. Iftner T, Villa LL (2003). Human papillomavirus technologies. Journal of the National Cancer Institute Monographs, 31: 80-88.
46. Jones DL, Alani RM, Munger K (1997). The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. Genes and Development, 11: 2101-2111.
47. Josefsson AM, Magnusson PK, Ylitalo N et al. (1998). p53 polymorphism and risk of cervical cancer. Nature, 396: 531.
48. Kaufmann AM, Backsch C, Schneider A et al. (2002). HPV induced cervical carcinogenesis: molecular basis and vaccine development. Zentralblatt für Gynäkologie, 124: 511-524.
49. Klaes R, Ridder R, Schaefer U et al. (1999). No evidence of p53 allelespecific predisposition in human papillomavirus-associated cervical cancer. Journal of Molecular Medicine, 77: 299-302.
50. Koutsky LA, Ault KA, Wheeler CM et al. (2002). A controlled trial of a human papillomavirus type 16 vaccine. New England Journal of Medicine, 347: 1645-1651.
51. Kutler DI, Wreesmann VB, Goberdhan A et al. (2003). Human papillomavirus DNA and p53 polymorphisms in squamous cell carcinomas from Fanconi anemia patients. Journal of the National Cancer Institute, 95: 1718-1721.
52. Laimins LA (1996). Human papillomaviruses target differentiating epithelium for virion production and malignant conversion. Seminars in Virology, 7: 305-313.
53. Lanham S, Campbell I, Watt P et al. (1998). p53 polymorphism and risk of cervical cancer. Lancet, 352: 1631.
54. Lazo PA (1999). The molecular genetics of cervical carcinoma. British Journal of Cancer, 80: 2008-2018.
55. Lizano M, Berumen J, Guido MC et al. (1997). Association between human papillomavirus type 18 variants and histopathology of cervical cancer. Journal of the National Cancer Institute, 89: 1227-1231.
56. Lorincz AT, Castle PE, Sherman ME et al. (2002). Viral load of human papillomavirus and risk of CIN3 or cervical cancer. Lancet, 360: 228-229.
57. McIntyre MC, Ruesch MN, Laimins LA (1996). Human papillomavirus E7 oncoproteins bind a single form of cyclin E in a complex with cdk2 and p107. Virology, 215: 73-82.
58. Mantovani F, Banks L (2001). The human papillomavirus E6 protein and its contribution to malignant progression. Oncogene, 20: 7874-7887.
59. Matsukura T, Koi S, Sugase M (1989). Both episomal and integrated forms of human papillomavirus type 16 are involved in invasive cervical cancers. Virology, 172: 63-72.
60. Meyers C, Frattini MG, Hudson JB et al. (1992). Biosynthesis of human papillomavirus from a continuous cell line upon epithelial differentiation. Science, 257: 971-973.
61. Minaguchi T, Kanamori Y, Matsushima M et al. (1998). No evidence of correlation between polymorphism at codon 72 of p53 and risk of cervical cancer in Japanese patients with human papillomavirus 16/18 infection. Cancer Research, 58: 4585-4586.
62. Montoya L, Saiz I, Rey G et al. (1998). Cervical carcinoma: human papillomavirus infection and HLA-associated risk factors in the Spanish population. European Journal of Immunogenetics, 25: 329-337.
63. Münger K, Howley PM (2002). Human papillomavirus immortalization and transformation functions. Virus Research, 89: 213-228.
64. Münger K, Phelps WC, Bubb V et al. (1989). The E6 and E7 genes of the human papillomavirus type 16 together are necessary and sufficient for transformation of primary human keratinocytes. Journal of Virology, 63: 4417-4421.
65. Münger K, Scheffner M, Huibregtse JM et al. (1992). Interactions of HPV E6 and E7 with tumor suppressor gene products. Cancer Surveys, 12: 197-217.
66. Münger K, Baldwin A, Edwards KM et al. (2004). Mechanisms of human papillomavirus-induced oncogenesis (review). Journal of Virology, 78 (21): 11451-11460.
67. Muñoz N, Bosch FX, de Sanjose S et al. (2003). Epidemiologic classification of human papillomavirus types associated with cervical cancer. New England Journal of Medicine, 348: 518-527.
68. Nindl I, Rindfleisch K, Lotz B et al. (1999). Uniform distribution of HPV 16 E6 and E7 variants in patients with normal histology, cervical intra-epithelial neoplasia and cervical cancer. International Journal of Cancer, 82: 203-207.
69. Nuovo GJ, Becker J, Margotta M et al. (1992). Histological distribution of polymerase chain reaction-amplified human papillomavirus 6 and 11 DNA in penile lesions. American Journal of Surgical Pathology, 16: 269-275.
70. Penn I (1986). Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer, 58: 611-616.
71. Pirami L, Giache V, Becciolini A (1997). Analysis of HPV16, 18, 31 and 35 DNA in pre-invasive and invasive lesions of the uterine cervix. Journal of Clinical Pathology, 50: 600-604.
72. Rosenthal AN, Ryan A, Al-Jehani RM et al. (1998). p53 codon 72 polymorphism and risk of cervical cancer in UK. Lancet, 352: 871-975.
73. Ruesch MN, Laimins LA (1998). Human papillomavirus oncoproteins alter differentiation-dependent cell cycle exit on suspension in semisolid medium. Virology, 250: 19-29.
74. Scheffner M, Werness BA, Huibregtse JM et al. (1990). The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes degradation of p53. Cell, 63: 1129-1136.
75. Schmitt A, Harry JB, Rapp B et al. (1994). Comparison of the properties of the E6 and E7 genes of low- and high-risk cutaneous papillomaviruses reveals strongly transforming and high Rb-binding activity for the E7 protein of the low-risk human papillomavirus type 1. Journal of Virology, 68: 7051-7059.
76. Sedman SA, Barbosa M, Vass WC et al. (1991). The full length E6 protein of human papillomavirus type 16 has transforming and transactivating activities and cooperates with E7 to immortalise keratinocytes in culture. Journal of Virology, 65: 4860-4866.
77. Sedman SA, Hubbert NL, Vass WC et al. (1992). Mutant p53 can substitute for human papillomavirus type 16 E6 in immortalization of human keratinocytes but does not have E6-associated trans-activation or transforming activity. Journal of Virology, 66: 4201-4208.
78. Sillman F, Stanek A, Sedlis A et al. (1984). The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. American Journal of Obstetrics and Gynecology, 150: 300-308.
79. Southern SA, Herrington CS (1998). Molecular events in uterine cervical cancer. Sexually Transmitted Infection, 74: 101-109.
80. Stanczuk GA, Sibanda EN, Perrey C et al. (2001). Cancer of the uterine cervix may be significantly associated with a gene polymorphism coding for increased IL-10 production. International Journal of Cancer, 94: 792-794.
81. Steenbergen RD, Kramer D, Braakhuis BJ et al. (2004). TSLC1 gene silencing in cervical cancer cell lines and cervical neoplasia. Journal of the National Cancer Institute, 96: 296-305.
82. Steinberg BM, Topp WC, Schneider PS et al. (1983). Laryngeal papillomavirus infection during clinical remission. New England Journal of Medicine, 308: 1261-1264.
83. Storey A, Thomas M, Kalita A et al.(1998) Role of a p53 polymorphism in the development of human papillomavirus-associated cancer. Nature 393 (6682): 229-234.
84. Stubenrauch F, Hummel M, Iftner T et al. (2000). The E8E2C protein, a negative regulator of viral transcription and replication, is required for extrachromosomal maintenance of human papillomavirus type 31 in keratinocytes. Journal of Virology, 74: 1178-1186.
85. Stubenrauch F, Zobel T, Iftner T (2001). The E8 domain confers a novel long-distance transcriptional repression activity on the E8E2C protein of high-risk human papillomavirus type 31. Journal of Virology, 75: 4139-4149.
86. Swan DC, Tucker RA, Holloway BP et al. (1997). A sensitive, typespecific, fluorogenic probe assay for detection of human papillomavirus DNA. Journal of Clinical Microbiology, 35: 886-891.
87. Swan DC, Tucker RA, Tortolero-Luna G et al.(1999) Human papillomavirus (HPV) DNA copy number is dependent on grade of cervical disease and HPV type. Journal of Clinical Microbiology 37: 1030-1034.
88. Syrjanen KJ (1989). Epidemiology of human papillomavirus (HPV) infections and their associations with genital squamous cell cancer. APMIS, 97: 957-970.
89. Talis AL, Huibregtse JM, Howley PM (1998). The role of E6AP in the regulation of p53 protein levels in human papillomavirus (HPV)- positive and HPV-negative cells. Journal of Biological Chemistry, 273: 6439-6445.
90. Tommasino M, Adamczewski JP, Carlotti F et al. (1993). HPV16E7 protein associates with the protein kinase p33CDK2 and cyclin A. Oncogene, 8: 195-202.
91. van Duin M, Snijders PJ, Vossen MT et al. (2000). Analysis of human papillomavirus type 16 E6 variants in relation to p53 codon 72 polymorphism genotypes in cervical carcinogenesis. Journal of General Virology, 81: 317-325.
92. van Duin M, Snijders PJ, Schrijnemakers HF et al. (2002). Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and viral clearance. International Journal of Cancer, 98: 590-595.
93. Villa LL, Sichero L, Rahal P et al. (2000). Molecular variants of human papillomavirus types 16 and 18 preferentially associated with cervical neoplasia. Journal of General Virology, 81: 2959-2968.
94. Villa LL, Costa RL, Petta CA et al. (2005). Prophylactic quadrivalent human papillomavirus (Type 6, 11, 16 and 18) L1 virus-like particle vaccine in young women: a randomised double blind placebocontrolled multi-centre phase 2 efficacy trial. Lancet Oncology, 615: 256-257.
95. Virmani AK, Muller C, Rathi A et al. (2001). Aberrant methylation during cervical carcinogenesis. Clinics in Cancer Research, 7: 584-589.
96. von Knebel-Döberitz M, Oltersdorf T, Schwarz E et al. (1988). Correlation of modified human papillomavirus early gene expression with altered growth properties in C4-1 cervical carcinoma cells. Cancer Research, 48: 3780-3786.
97. von Knebel-Döberitz M, Rittmüller C, zur Hausen H et al. (1992). Inhibition of tumourigenicity of cervical cancer cells in nude mice by HPV E6-E7 anti-sense RNA. International Journal of Cancer, 51: 831-834.
98. Walboomers JMM, Jacobs MV, Manos MM et al.(1999) Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. Journal of Pathology 189: 12-19.
99. Werness BA, Levine AJ, Howley PM (1990). Association of human papillomavirus types 16 and 18 E6 proteins with p53. Science, 248: 76-79.
100. Wilson VG, West M, Woytek K et al. (2002). Papillomavirus E1 proteins:form, function, and features. Virus Genes, 24: 275-290.
101. Xi LF, Koutsky LA, Galloway DA et al. (1997). Genomic variation of human papillomavirus type 16 and risk for high grade cervical intraepithelial neoplasia. Journal of the National Cancer Institute, 89: 796-802.
102. Yamada T, Manos MM, Peto J et al. (1995). Human papillomavirus type 16 sequence variation in cervical cancers: a worldwide perspective. Journal of Virology, 71: 2463-2472.
103. Yee AS, Shih HH, Tevosian SG (1998) New perspectives on retinoblastoma family functions in differentiation. Frontiers in Bioscience 3:D532-D547.
104. Ylitalo N, Sorensen P, Josefsson AM et al. (2000). Consistent high viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case-control study. Lancet, 355: 2194-2198.
105. Zehbe I, Voglino G, Delius H et al. (1988a). Risk of cervical cancer and geographical variations of human papillomavirus 16 E6 polymorphisms. Lancet, 352: 1441-1442.
106. Zehbe I, Wilander E, Delius H et al. (1998b). Human papillomavirus 16 E6 variants are more prevalent in invasive cervical carcinoma than the prototype. Cancer Research, 58: 829-833.
107. Zehbe I, Voglino G, Wilander E et al. (2001). p53 codon 72 polymorphism and various human papillomavirus 16 E6 genotypes are risk factors for cervical cancer development. Cancer Research, 61: 608-611.
108. Zerfass-Thome K, Zwerschke W, Mannhardt B et al. (1996). Inactivation of the cdk inhibitor p27KIP1 by the human papillomavirus type 16 E7 oncoprotein. Oncogene, 13: 2323-2330.
109. Zobel T, Iftner T, Stubenrauch F (2003) The papillomavirus E8-E2C protein represses DNA replication from extrachromosomal origins. Molecular and Cellular Biology 23: 8352-8362.
110. zur Hausen H (1996). Roots and perspectives of contemporary papillomavirus research. Journal of Cancer Research and Clinical Oncology, 122 (1): 3-13.
111. zur Hausen H (2000). Papillomaviruses causing cancer: evasion from host-cell control in early event in carcinogenesis. Journal of the National Cancer Institute, 92: 690-698.